Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab

Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Retrospective Analysis of PD-L1 Immunohistochemistry Assays

Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, discusses a retrospective analysis on the effectiveness of the VENTANA PD-L1 SP14...

Ian E. Krop, MD, PhD, on Trastuzumab Deruxtecan for Patients With Previously Treated, HER2-Positive Metastatic Breast Cancer

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses phase II trial findings on trastuzumab deruxtecan, a HER2-targeting antibody-drug conjugate, in patients with...

Hope S. Rugo, MD, on HER2-Positive Metastatic Breast Cancer: SOPHIA Trial of Chemotherapy Plus Margetuximab or Trastuzumab

Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, discusses trial data on margetuximab plus chemotherapy, which improved progressio...

Joseph Sparano, MD: The William L. McGuire Memorial Lecture

Joseph Sparano, MD, of the Montefiore Medical Center, discusses three challenges:

• How can gene-expression profiles and other diagnostic tests be us...

Terry P. Mamounas, MD, MPH, on Extending Letrozole Treatment in Hormone Receptor–Positive Breast Cancer

Terry P. Mamounas, MD, MPH, of Orlando Health UF Health Cancer Center, discusses 10-year results from NRG Oncology/NSABP B-42, which showed that, for postmenopausal women wit...